BridgeBio Announces FDA Clearance Of IND Application For BBO-8520, A First-in-class Direct Inhibitor Of KRASG12C

Wednesday, January 3, 2024 1 min read

Key Takeaway: BridgeBio Announces FDA Clearance Of IND Application For BBO-8520, A First-in-class Direct Inhibitor Of KRASG12C

Full Press Release Details

BridgeBio Announces FDA Clearance Of IND Application For BBO-8520, A First-in-class Direct Inhibitor Of KRASG12C.